Bloxham D P, Chalkley R A, Coghlin S J, Salam W
Biochem J. 1978 Dec 1;175(3):999-1011. doi: 10.1042/bj1750999.
A general route for the synthesis of chloromethyl ketone derivatives of fatty acids is described. 5-Chloro-4-oxopentanoic acid, 7-chloro-6-oxoheptanoic acid, 9-chloro-8-oxononanoic acid and 11-chloro-10-oxoundecanoic acid were synthesized by this method and tested as covalent inhibitors of pig heart acetoacetyl-CoA thiolase. The K1 decreased by approx. 20-fold for each pair of methylenes added to the chain length, showing that the initial stage in inhibitor binding occurs at a non-polar region of the protein. This region is probably located at the enzyme active site, since inhibition was prevented by acetoacetyl-CoA or acetyl-CoA but not by CoA. The site of modification by chloromethyl ketone derivatives of fatty acids is restricted to a thiol group, since inactivation of the enzyme was prevented by reversible thiomethylation of the active-site thiol. In contrast, an amino-directed reagent, citraconic anhydride, still inactivated the enzyme, even when the active-site thiol was protected. Evidence that the enzyme thiol was particularly reactive came from studies on the pH-dependence of the alkylation reaction and thiol-competition experiments. Inhibition of the enzyme proceeded suprisingly well at acidic pH values and a 10(5) molar excess of external thiol over active-site thiol was required to prevent inhibition by 0.3 mM-9-chloro-8-oxononanoic acid. In addition to inhibiting isolated acetoacetyl-CoA thiolase, in hepatocytes the chloromethyl ketone derivatives of fatty acids also inhibited chloresterol synthesis, which uses this enzyme as an early step in the biosynthetic pathway. In isolated cells, the chloromethyl ketone derivatives of fatty acids were considerably less specific in their inhibitory action compared with 3-acetylenic derivatives of fatty acids, which act as suicide inhibitors of acetoacetyl-CoA thiolase. However, 9-chloro-8-oxononanoic acid was also an effective inhibitor of both hepatic cholesterol and fatty acid synthesis in mice in vivo, whereas the acetylenic fatty acid derivative, dec-3-ynoic acid, was completely ineffective. The effective inhibitory dose of 9-chloro-8-oxononanoic acid (2.5-5 mg/kg) was substantially lower than the estimated LD50 for the inhibitor (100 mg/kg).
本文描述了一种合成脂肪酸氯甲基酮衍生物的通用方法。通过该方法合成了5-氯-4-氧代戊酸、7-氯-6-氧代庚酸、9-氯-8-氧代壬酸和11-氯-10-氧代十一烷酸,并将其作为猪心脏乙酰乙酰辅酶A硫解酶的共价抑制剂进行了测试。每增加一对亚甲基到链长,K1降低约20倍,这表明抑制剂结合的初始阶段发生在蛋白质的非极性区域。该区域可能位于酶的活性位点,因为乙酰乙酰辅酶A或乙酰辅酶A可阻止抑制作用,而辅酶A则不能。脂肪酸氯甲基酮衍生物的修饰位点仅限于一个硫醇基团,因为活性位点硫醇的可逆硫甲基化可阻止酶的失活。相比之下,一种氨基导向试剂柠康酸酐即使在活性位点硫醇被保护时仍能使酶失活。关于酶硫醇特别具有反应性的证据来自对烷基化反应的pH依赖性研究和硫醇竞争实验。在酸性pH值下,酶的抑制作用出人意料地良好,并且需要活性位点硫醇105倍摩尔过量的外部硫醇才能防止0.3 mM 9-氯-8-氧代壬酸的抑制作用。除了抑制分离的乙酰乙酰辅酶A硫解酶外,在肝细胞中,脂肪酸的氯甲基酮衍生物还抑制胆固醇合成,胆固醇合成在生物合成途径的早期步骤中使用该酶。在分离的细胞中,与作为乙酰乙酰辅酶A硫解酶自杀抑制剂的脂肪酸3-炔基衍生物相比,脂肪酸的氯甲基酮衍生物在其抑制作用方面的特异性要低得多。然而,9-氯-8-氧代壬酸在体内对小鼠肝脏胆固醇和脂肪酸合成也是一种有效的抑制剂,而炔基脂肪酸衍生物癸-3-炔酸则完全无效。9-氯-8-氧代壬酸的有效抑制剂量(2.5-5 mg/kg)大大低于该抑制剂的估计半数致死剂量(100 mg/kg)。